Iterum Therapeutics has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ITRM:
- Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
- Biotech Alert: Searches spiking for these stocks today
- Iterum Therapeutics reports Q3 EPS (30c) vs ($2.38) last year
- Iterum Therapeutics Reports Third Quarter 2023 Financial Results
- Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023